Bio-Rad Laboratories, Inc. (BIO) wird mit einem nachlaufenden KGV von gehandelt 9.8, erwartetes KGV von 28.8. Die nachlaufende Gewinnrendite beträgt 10.15%, erwartete Gewinnrendite 3.48%. PEG 2.48. Die Graham-Zahl beträgt $418.48.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 64/100 mit 3/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | 190.8 | -2.50 | 2.08 | 2.59 | - |
| 2017 | 61.7 | 0.17 | 2.42 | 3.28 | - |
| 2018 | 19.2 | 0.10 | 1.72 | 3.03 | - |
| 2019 | 6.3 | 0.02 | 1.92 | 4.78 | - |
| 2020 | 4.5 | 0.04 | 1.76 | 6.82 | - |
| 2021 | 5.3 | 0.46 | 1.65 | 7.71 | - |
| 2022 | -3.5 | 0.02 | 1.30 | 4.47 | - |
| 2023 | -14.8 | 0.18 | 1.08 | 3.53 | - |
| 2024 | -5.0 | -0.03 | 1.41 | 3.61 | - |
| 2025 | 10.9 | -0.08 | 1.11 | 3.20 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $0.88 | $2.07B | $28.13M | 1.4% |
| 2017 | $4.07 | $2.16B | $114.74M | 5.3% |
| 2018 | $11.94 | $2.29B | $361M | 15.8% |
| 2019 | $58.27 | $2.31B | $1.76B | 76.1% |
| 2020 | $126.20 | $2.55B | $3.81B | 149.8% |
| 2021 | $140.83 | $2.92B | $4.25B | 145.6% |
| 2022 | $-121.79 | $2.8B | $-3.63B | -129.5% |
| 2023 | $-21.82 | $2.67B | $-637.32M | -23.9% |
| 2024 | $-65.36 | $2.57B | $-1.84B | -71.9% |
| 2025 | $27.87 | $2.58B | $759.9M | 29.4% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $10.25 | $10.05 – $10.43 | $2.63B | $2.59B – $2.66B | 2 |
| 2027 | $11.57 | $11.35 – $11.78 | $2.72B | $2.62B – $2.82B | 2 |
| 2028 | $12.61 | $12.38 – $12.85 | $2.81B | $2.78B – $2.83B | 1 |
| 2029 | $14.30 | $14.03 – $14.56 | $2.94B | $2.9B – $2.98B | 1 |
